These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study. Seto T; Hayashi H; Satouchi M; Goto Y; Niho S; Nogami N; Hida T; Takahashi T; Sakakibara-Konishi J; Morise M; Nagasawa T; Suzuki M; Ohkura M; Fukuhara K; Thurm H; Peltz G; Nishio M Cancer Sci; 2020 Oct; 111(10):3726-3738. PubMed ID: 32681682 [TBL] [Abstract][Full Text] [Related]
5. Real world study of safety and efficacy of lorlatinib as second line and beyond in Biswas B; Ghadyalpatil NS; Patil S; Patel A; Ganguly S; Rathore A; Guleria B; Tarannum CF; Ghosh J; Kondapally MS; Thippeswamy R; Reddy SHP; Roy S Ecancermedicalscience; 2024; 18():1667. PubMed ID: 38439810 [TBL] [Abstract][Full Text] [Related]
6. Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study. Girard N; Galland-Girodet S; Avrillon V; Besse B; Duruisseaux M; Cadranel J; Otto J; Prevost A; Roch B; Bennouna J; Bouledrak K; Coudurier M; Egenod T; Lamy R; Ricordel C; Moro-Sibilot D; Odier L; Tillon-Strozyk J; Zalcman G; Missy P; Westeel V; Baldacci S ESMO Open; 2022 Apr; 7(2):100418. PubMed ID: 35227966 [TBL] [Abstract][Full Text] [Related]
7. LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC. Alexander M; Wei J; Parakh S; John T; Kao S; Nagrial A; Bowyer S; Warburton L; Moore M; Hughes BGM; Clay TD; Pavlakis N; Solomon BJ; Itchins M JTO Clin Res Rep; 2023 Apr; 4(4):100490. PubMed ID: 37077199 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor. Lee J; Sun JM; Lee SH; Ahn JS; Park K; Choi Y; Ahn MJ Clin Lung Cancer; 2019 May; 20(3):215-221. PubMed ID: 30683630 [TBL] [Abstract][Full Text] [Related]
10. Later-Line Treatment with Lorlatinib in Hochmair MJ; Fabikan H; Illini O; Weinlinger C; Setinek U; Krenbek D; Prosch H; Rauter M; Schumacher M; Wöll E; Wass R; Brehm E; Absenger G; Bundalo T; Errhalt P; Urban M; Valipour A Pharmaceuticals (Basel); 2020 Nov; 13(11):. PubMed ID: 33171712 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial. Soo RA; Huat Tan E; Hayashi H; Seto T; Lin CC; Ou SI; Kim DW; Liu G; Abbattista A; Martini JF; Hooi Wong C; Toffalorio F; Solomon BJ Lung Cancer; 2022 Jul; 169():67-76. PubMed ID: 35660971 [TBL] [Abstract][Full Text] [Related]
12. A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib. Schneider JL; Muzikansky A; Lin JJ; Krueger EA; Lennes IT; Jacobson JO; Cheng M; Heist RS; Piotrowska Z; Gainor JF; Shaw AT; Dagogo-Jack I JTO Clin Res Rep; 2022 Jul; 3(7):100347. PubMed ID: 35815322 [TBL] [Abstract][Full Text] [Related]
13. An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC. Zhu VW; Lin YT; Kim DW; Loong HH; Nagasaka M; To H; Ang YL; Ock CY; Tchekmedyian N; Ou SI; Syn NL; Reungwetwattana T; Lin CC; Soo RA J Thorac Oncol; 2020 Sep; 15(9):1484-1496. PubMed ID: 32360579 [TBL] [Abstract][Full Text] [Related]
14. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378 [TBL] [Abstract][Full Text] [Related]
15. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. Shaw AT; Solomon BJ; Chiari R; Riely GJ; Besse B; Soo RA; Kao S; Lin CC; Bauer TM; Clancy JS; Thurm H; Martini JF; Peltz G; Abbattista A; Li S; Ou SI Lancet Oncol; 2019 Dec; 20(12):1691-1701. PubMed ID: 31669155 [TBL] [Abstract][Full Text] [Related]
17. Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib. De Giglio A; Lamberti G; Facchinetti F; Genova C; Andrini E; Dal Bello MG; Tiseo M; Metro G; Chiari R; Ricciuti B Clin Lung Cancer; 2020 Sep; 21(5):e478-e487. PubMed ID: 32409267 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis. Peng L; Lu D; Xia Y; Hong S; Selvaggi G; Stebbing J; Sun Y; Liang F Front Oncol; 2021; 11():754768. PubMed ID: 34820326 [TBL] [Abstract][Full Text] [Related]
19. Combined Lorlatinib, Dabrafenib, and Trametinib Treatment for Li D; Liu J; Zhang X; Han J; Jin H; Wang L; Feng L; Fan Z; Zuo J; Wang Y Cancer Manag Res; 2022; 14():3175-3179. PubMed ID: 36411743 [TBL] [Abstract][Full Text] [Related]
20. First-Line Lorlatinib or Crizotinib in Advanced Shaw AT; Bauer TM; de Marinis F; Felip E; Goto Y; Liu G; Mazieres J; Kim DW; Mok T; Polli A; Thurm H; Calella AM; Peltz G; Solomon BJ; N Engl J Med; 2020 Nov; 383(21):2018-2029. PubMed ID: 33207094 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]